Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

Published on 7 Jan 2025 on Zacks · via Yahoo Finance

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of...

Read the rest of the article

Start tracking your investments with Statfolio

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from...

TipRanks · via Yahoo Finance 11 Jan 2025

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stag...

Zacks · via Yahoo Finance 10 Jan 2025

On Thursday, Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating th...

Benzinga · via Yahoo Finance 9 Jan 2025

Vaccine stocks and EV maker Lucid Technologies (LCID) are among today’s biggest winners today. Va...

Insider Monkey · via Yahoo Finance 7 Jan 2025

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis ...

Zacks · via Yahoo Finance 7 Jan 2025

SNY's reasonable valuation, improving top-line performance, contributions from new product launch...

Zacks · via Yahoo Finance 7 Jan 2025

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales...

Zacks · via Yahoo Finance 6 Jan 2025

Duquesne Family Office's chief is cashing in his chips on two leading artificial intelligence (AI...

The Motley Fool · via AOL 24 Dec 2024

(You can read the full research report on United-Guardian here >>>) Why Haven't You Looked at Zac...

Zacks · via Yahoo Finance 24 Dec 2024

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to...

Zacks · via Yahoo Finance 23 Dec 2024